Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NORTHSTAR Phase 3 study of ALK-001 in Stargardt disease
jRCT2031260457Phase 3Not yet recruiting
- Sponsor
- Alkeus Pharmaceuticals, Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Fundus Flavimaculatus (FF) comparing ALK-001 with Placebo (2 arms). Primary endpoint: Annualized growth rate of retinal atrophic lesions. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
gildeuretinol
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on jRCT2031260457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260457.